Sep 16, 2020

An Experimental Drug Protects Covid-19 Patients, Eli Lilly Claims

Posted by in category: biotech/medical

A single infusion of an experimental drug markedly reduced levels of the coronavirus in newly infected patients and lowered the chances that they would need hospitalization, the drug’s maker announced on Wednesday.

The drug is a monoclonal antibody, a manufactured copy of an antibody produced by a patient who recovered from Covid-19, the illness caused by the coronavirus. Many scientists hope that monoclonal antibodies will prove to be powerful treatments for Covid-19, but they are difficult and expensive to manufacture, and progress has been slow.

A so-called monoclonal antibody lowered levels of the coronavirus and prevented hospitalizations. The research has not yet been vetted by independent experts.

Leave a reply